

**WEST SUFFOLK HOSPITAL FOUNDATION TRUST: Formulary Adherence Checklist for NICE Technology Appraisals About Medicines (January 2016)**

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS.

| Technology appraisal (TA)<br><small>Titles are hyperlinks to full guidance</small>   | Date of TA Release | Availability of medicine for NHS patients with this medical condition, as indicated by NICE   | Trust Allocation for Action                               | Trust Action Required before Implementation | Adherence of local formulary to NICE |                                 |                                      |                             | Other information        |               |  |
|--|--------------------|---|---|---|--------------------------------------|---------------------------------|--------------------------------------|-----------------------------|--------------------------|---------------|--|
|  |                    |   |   |   | Yes<br>(mark 'x' if applicable)      | N/A<br>(mark 'x' if applicable) | Date of local decision<br>(DD/MM/YY) | Time to implement<br>(days) | Responsible Commissioner | Tariff Status | Notes (e.g. rationale, method of making available) |
| <b>2015-2016</b>   |                    |   |   |   |                                      |                                 |                                      |                             |                          |               |  |
| <a href="#">Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) [TA382]</a>  | 27/01/2016         | <b>Eltrombopag</b> - unable to make a recommendation because no evidence submission was received from Novartis for the technology.  | Dr Young-Min<br>A Campbell<br>P Alderton<br>S Bougatsias  | Ratify at next D&T meeting                  | X                                    |                                 | 26/04/2016                           | 90                          | NHSE                     | Excluded      | For discussion at March D&T                        |
| <a href="#">Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy [TA381]</a> | 27/01/2016         | <b>Olaparib</b> is recommended as an option for treating adults with relapsed, platinum sensitive ovarian, fallopian tube or peritoneal cancer who have BRCA1 or BRCA2 mutations and whose disease has responded to platinum based chemotherapy.  | Dr Moody<br>A Campbell<br>P Alderton<br>J Esterhuizen     | Nil (complete)                              |                                      | X                               | 26/04/2016                           | 90                          | NHSE                     | Excluded      | This guidance is not relevant to WSH               |
| <a href="#">Panobinostat for treating multiple myeloma after at least 2 previous treatments [TA380]</a>  | 27/01/2016         | <b>Panobinostat</b> in combination with bortezomib and dexamethasone is recommended as an option for treating multiple myeloma  | Dr Karanth<br>K Mc Kinnon<br>P Alderton<br>S Bougatsias   | Add drug to formulary                       | X                                    |                                 | 26/04/2016                           | 90                          | NHSE                     | Excluded      | For discussion at March D&T                        |
| <a href="#">Nintedanib for treating idiopathic pulmonary fibrosis [TA379]</a>  | 27/01/2016         | <b>Nintedanib</b> is recommended as an option for treating idiopathic pulmonary fibrosis  |   | Confirm relevance to trust                  |                                      | X                               | 26/04/2016                           | 90                          |                          | Excluded      | For discussion at March D&T                        |
| <a href="#">Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy [TA378]</a>  | 27/01/2016         | <b>Ramucirumab</b> alone or with paclitaxel is not recommended for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.  | Dr Patterson<br>A Campbell<br>P Alderton<br>J Esterhuizen | Confirm relevance to trust                  | X                                    |                                 | 26/04/2016                           | 90                          | NHSE                     | Excluded      | For discussion at March D&T                        |
| <a href="#">Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated [TA377]</a>   | 27/01/2016         | <b>Enzalutamide</b> is recommended as an option for treating metastatic hormone-relapsed prostate cancer  | Dr Woodward<br>B van Rooyen<br>P Alderton<br>S Bougatsias | Add drug to formulary                       | X                                    |                                 | 26/04/2016                           | 90                          | NHSE                     | Excluded      | For discussion at March D&T                        |
| <a href="#">Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases [TA376]</a>   | 27/01/2016         | <b>Radium-223 dichloride</b> is recommended as an option for treating adults with hormone-relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases.   |   | Confirm relevance to trust                  |                                      | X                               | 26/04/2016                           | 90                          | NHSE                     | Excluded      | For discussion at March D&T                        |
| <a href="#">Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed [TA375]</a>           | 26/01/2016         | Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept, all in combination with methotrexate, are recommended as options for treating rheumatoid arthritis, and adalimumab, etanercept, certolizumab pegol or tocilizumab can be used as monotherapy for people who cannot take methotrexate because it is contraindicated or because of intolerance. | Dr O Reilly<br>A Campbell<br>P Alderton<br>J Esterhuizen  | Add drugs to formulary. Discuss pathway     | X                                    |                                 | 25/04/2016                           | 90                          | CCG                      | Excluded      | For discussion at March D&T                        |

| Technology appraisal (TA)<br>Titles are hyperlinks to full guidance  | Date of TA Release | Availability of medicine for NHS patients with this medical condition, as indicated by NICE  | Trust Allocation for Action                               | Trust Action Required before Implementation | Adherence of local formulary to NICE |                                 |                                      |                             | Other Information        |               |  |
|--|--------------------|--|---|---|--------------------------------------|---------------------------------|--------------------------------------|-----------------------------|--------------------------|---------------|--|
|  |                    |  |   |   | Yes<br>(mark 'x' if applicable)      | N/A<br>(mark 'x' if applicable) | Date of local decision<br>(DD/MM/YY) | Time to implement<br>(days) | Responsible Commissioner | Tariff Status | Notes (e.g. rationale, method of making available)   |
| <b>2015-2016</b>   |                    |  |   |   |                                      |                                 |                                      |                             |                          |               |  |
| <a href="#">Erlotinib &amp; gefitinib (post chemotherapy) for treating non-small-cell lung cancer (TA 374)</a>                                       | 16/12/2015         | <b>Erlotinib</b> - recommended as an option for treating locally advanced or metastatic NSCLC that has progressed in people after non-targeted chemotherapy because of delayed confirmation that their tumour is EGFR-TK mutation-positive.<br><b>Gefitinib</b> - not recommended for treating locally advanced or metastatic NSCLC that has progressed after non-targeted chemotherapy in mpeople with EGFR-TK mutation-negative tumours. | Dr Patterson<br>A Campbell<br>P Alderton<br>J Esterhuizen | Nil (complete)                              | X                                    |                                 | 15/03/2016                           | 90                          | NHSE                     | Excluded      | WSH confirms that erlotinib will be used at the trust for this indication, in line with NICE guidance.<br>WSH confirms that gefitinib will not be used at the trust for this indication, in line with NICE guidance. |
| <a href="#">Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA 373)</a>                                | 16/12/2015         | <b>Abatacept, adalimumab, etanercept and tocilizumab</b> - recommended as options for treating polyarticular JIA   | Dr Powell<br>B Bramble<br>J Esterhuizen                   | Add drugs to formulary. Discuss pathway     | X                                    |                                 | 15/03/2016                           | 90                          | NHSE                     | Excluded      |  |
| <a href="#">Apremilast for active psoriatic arthritis (TA 372)</a>   | 16/12/2015         | <b>Apremilast</b> - alone or in combination with DMARD therapy is not recommended for treating adults with active psoriatic arthritis that has not responded to prior DMARD therapy, or such therapy is not tolerated  | Dr O Reilly<br>A Campbell<br>P Alderton<br>J Esterhuizen  | Nil (complete)                              | X                                    |                                 | 13/01/2016                           | 28                          | CCG                      | Excluded      | WSH confirms that this drug will not be used at the trust for this indication, in line with NICE guidance.   |
| <a href="#">Trastuzumab emtansine for unresectable metastatic HER2-positive breast cancer after treatment with trastuzumab and a taxane (TA 371)</a> | 16/12/2015         | <b>Trastuzumab emtansine</b> - not recommended for treating adults with HER2-positive, unresectable locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane  | Dr Moody<br>A Campbell<br>P Alderton<br>J Esterhuizen     | Nil (complete)                              | X                                    |                                 | 13/01/2016                           | 28                          | NHSE                     | Excluded      | WSH confirms that this drug will not be used at the trust for this indication, in line with NICE guidance.   |
| <a href="#">Bortezomib for previously untreated mantle cell lymphoma (TA 370)</a>  | 16/12/2015         | <b>Bortezomib</b> - recommended as an option for previously untreated mantle cell lymphoma in adults for whom haematopoietic stem cell transplantation is unsuitable   | Dr Karanth<br>A Campbell<br>P Alderton<br>J Esterhuizen   | Add drugs to formulary. Discuss pathway     | X                                    |                                 | 15/03/2016                           | 90                          | NHSE                     | Excluded      |  |
| <a href="#">Ciclosporin for dry eye disease (TA 369)</a>   | 16/12/2015         | <b>Ciclosporin</b> - recommended as option for severe keratitis in patients with dry eye disease that has not improved after treatment with tear substitutes   | Mrs Cates<br>S Taylor<br>T Bunting<br>J Esterhuizen       | Add drug to formulary. Discuss pathway      | X                                    |                                 | 15/03/2016                           | 90                          | CCG                      | Included      |  |
| <a href="#">Apremilast for moderate to severe plaque psoriasis (TA 368)</a>  | 25/11/2015         | <b>Apremilast</b> - not recommended for treating adults with moderate to severe chronic plaque psoriasis   | Dr Jenkins<br>B van Rooyen<br>P Alderton<br>J Esterhuizen | Nil (complete)                              | X                                    |                                 | 02/12/2015                           | 7                           | CCG                      | Excluded      | WSH confirms that this drug will not be used at the trust for this indication, in line with NICE guidance.   |
| <a href="#">Vortioxetine for major depressive episodes (TA 367)</a>  | 25/11/2015         | <b>Vortioxetine</b> - recommended as option for treating major depressive episodes in adults (responded inadequately to 2 antidepressants within current episode   | N/A   | Nil (complete)                              |                                      | X                               | 02/12/2015                           | 7                           | CCG                      | Included      | This guidance is not relevant to WSH   |
| <a href="#">Pembrolizumab for advanced melanoma (TA 366)</a>   | 25/11/2015         | <b>Pembrolizumab</b> - recommended as an option for treating advanced melanoma that has not been previously treated with ipilimumab  | Dr Jenkins<br>B van Rooyen<br>P Alderton<br>J Esterhuizen | Nil (complete)                              |                                      | X                               | 02/12/2015                           | 7                           | NHSE                     | Excluded      | This guidance is not relevant to WSH   |
| <a href="#">Ombitasvir-Pariaprevir-Ritonavir for chronic hepatitis C (TA 365)</a>  | 25/11/2015         | <b>Ombitasvir-Paritaprevir-Ritonavir</b> - recommended as an option for treating genotype 1 or 4 chronic hepatitis C in adults   | Dr Whalley<br>A Campbell<br>P Alderton<br>J Esterhuizen   | Add drug to formulary. Discuss pathway      | X                                    |                                 | 23/02/2016                           | 90                          | NHSE                     | Excluded      |  |
| <a href="#">Daclatasvir for chronic hepatitis C (TA 364)</a>   | 25/11/2015         | <b>Daclatasvir</b> - recommended as an option for treating chronic hepatitis C in adults   | Dr Whalley<br>A Campbell<br>P Alderton<br>J Esterhuizen   | Add drug to formulary. Discuss pathway      | X                                    |                                 | 23/02/2016                           | 90                          | NHSE                     | Excluded      |  |
| <a href="#">Ledipasvir-Sofosbuvir for chronic hepatitis C (TA 363)</a>   | 25/11/2015         | <b>Ledipasvir-Sofosbuvir</b> - recommended as an option for treating chronic hepatitis C in adults   | Dr Whalley<br>A Campbell<br>P Alderton<br>J Esterhuizen   | Add drug to formulary. Discuss pathway      | X                                    |                                 | 23/02/2016                           | 90                          | NHSE                     | Excluded      |  |

| Technology appraisal (TA)<br>Titles are hyperlinks to full guidance   | Date of TA Release | Availability of medicine for NHS patients with this medical condition, as indicated by NICE  | Trust Allocation for Action                                  | Trust Action Required before Implementation | Adherence of local formulary to NICE |                              |                                   |                          | Other Information        |               |   |
|---|--------------------|--|--|---|--------------------------------------|------------------------------|-----------------------------------|--------------------------|--------------------------|---------------|---|
|   |                    |  |  |   | Yes (mark 'x' if applicable)         | N/A (mark 'x' if applicable) | Date of local decision (DD/MM/YY) | Time to implement (days) | Responsible Commissioner | Tariff Status | Notes (e.g. rationale, method of making available)  |
| <b>2015-2016</b>  |                    |  |  |   |                                      |                              |                                   |                          |                          |               |   |
| <a href="#">Paclitaxel (with carboplatin) for untreated NSCLC (TA 362)</a>  | 28/10/2015         | <b>Paclitaxel</b> - unable to make a recommendation because no evidence submission was received from the manufacturer for this technology  | N/A  | Nil (complete)                              | X                                    |                              | 28/10/2015                        | 0                        | NHSE                     | Excluded      | Terminated appraisal. WSH confirms that this drug is not currently used for any patient and will not be used in the future for this indication. |
| <a href="#">Simeprevir (with sofosbuvir) for hepatitis C (TA 361)</a>   | 28/10/2015         | <b>Simeprevir</b> - unable to make a recommendation because no evidence submission was received from the manufacturer for this technology  | N/A  | Nil (complete)                              |                                      | X                            | 28/10/2015                        | 0                        | NHSE                     | Excluded      | Terminated appraisal. WSH confirms that this drug is not currently used for any patient and will not be used in the future for this indication. |
| <a href="#">Paclitaxel (with gemcitabine) for previously untreated metastatic pancreatic cancer (TA 360)</a>                                  | 28/10/2015         | <b>Paclitaxel</b> - as albumin-bound nanoparticles in combination with gemcitabine is not recommended for adults with previously untreated metastatic adenocarcinoma of the pancreas   | Dr Patterson B<br>van Rooyen<br>P Alderton<br>J Esterhuizen  | Nil (complete)                              | X                                    |                              | 04/11/2015                        | 7                        | NHSE                     | Excluded      | WSH confirms that this drug will not be used at the trust for this indication, in line with NICE guidance.                                      |
| <a href="#">Idelalisib for chronic lymphocytic leukaemia (TA 359)</a>   | 28/10/2015         | <b>Idelalisib</b> - in combination with rituximab recommended for untreated CLL in adults with 17p deletion or TP53, or for CLL in adults when disease has been treated but relapsed within 24 months  | Dr Young-Min B<br>van Rooyen<br>P Alderton<br>S Bougatsias   | Nil (complete)                              | X                                    |                              | 26/01/2016                        | 90                       | NHSE                     | Excluded      | WSH confirms that this drug will be used in line with NICE guidance. Drug added to formulary.   |
| <a href="#">Tolvaptan for autosomal dominant polycystic kidney disease (TA 358)</a>   | 28/10/2015         | <b>Tolvaptan</b> - recommended as option for treating autosomal dominant polycystic kidney disease in defined patient groups   | Dr Yiu B<br>van Rooyen<br>P Alderton<br>J Esterhuizen        | Nil (complete)                              | X                                    |                              | 26/01/2016                        | 90                       | CCG                      | Excluded      | Whilst Dr Yiu is on leave it is unlikely that tolvaptan will be initiated at WSH (patients will be referred to Addenbrookes for management).    |
| <a href="#">Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)</a>                                | 07/10/2015         | <b>Pembrolizumab</b> - recommended as an option for treating advanced (unresectable or metastatic) melanoma.   | Dr Jenkins B<br>van Rooyen<br>P Alderton<br>J Esterhuizen    | Nil (complete)                              |                                      | X                            | 04/11/2015                        | 28                       | NHSE                     | Excluded      | This guidance is not relevant to WSH  |
| <a href="#">Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355)</a>                  | 30/09/2015         | <b>Edoxaban</b> - recommended as an option for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation with one or more risk factors (congestive heart failure, hypertension, diabetes, prior stroke or transient ischaemic attack, age ≥75 years) | Dr Chitnavis B<br>van Rooyen<br>P Alderton<br>J Esterhuizen  | Nil (complete)                              | X                                    |                              | 29/12/2015                        | 90                       | CCG                      | Included      | WSH confirms that this drug will be used in line with NICE guidance. Drug added to formulary. Traffic light confirmed as BLUE.                  |
| <a href="#">Ruxolitinib for treating polycythaemia vera (TA356)</a>   | 30/09/2015         | <b>Ruxolitinib</b> - unable to make a recommendation because no evidence submission was received from Novartis Pharmaceuticals for the technology.   | N/A  | Nil (complete)                              | X                                    |                              | 30/09/2015                        | 0                        | NHSE                     | Excluded      | Terminated appraisal. WSH confirms that this drug is not currently used for any patient and will not be used in the future for this indication. |
| <a href="#">Bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (TA353)</a> | 31/08/2015         | <b>Bevacizumab</b> - unable to make a recommendation because no evidence submission was received from Roche Products for the technology.   | N/A  | Nil (complete)                              |                                      | X                            | 31/08/2015                        | 0                        | NHSE                     | Excluded      | Terminated appraisal  |
| <a href="#">Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)</a>                                  | 31/08/2015         | <b>Edoxaban</b> - recommended as an option for treating and for preventing recurrent deep vein thrombosis and pulmonary embolism in adults.  | Dr Chitnavis B<br>van Rooyen<br>P Alderton<br>J Esterhuizen  | Nil (complete)                              | X                                    |                              | 29/11/2015                        | 90                       | CCG                      | Included      | WSH confirms that this drug will be used in line with NICE guidance. Drug added to formulary. Traffic light status confirmed as GREEN.          |
| <a href="#">Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)</a>                            | 31/08/2015         | <b>Vedolizumab</b> - recommended as an option for treating moderately to severely active Crohn's disease   | Dr Sharpstone B<br>van Rooyen<br>P Alderton<br>J Esterhuizen | Nil (complete)                              | X                                    |                              | 29/11/2015                        | 90                       | CCG                      | Excluded      | WSH confirms that this drug will be used in line with NICE guidance. Drug added to formulary. Pathway confirmation required.                    |
| <a href="#">Aflibercept for treating diabetic macular oedema (TA346)</a>  | 31/07/2015         | <b>Aflibercept</b> - recommended as an option for treating visual impairment caused by diabetic macular oedema   | Mr Gupta<br>Steve Myers<br>C McFarlane<br>J Esterhuizen      | Nil (complete)                              | X                                    |                              | 29/10/2015                        | 90                       | CCG                      | Excluded      | WSH confirms that this drug will be used in line with NICE guidance. Drug added to formulary. Pathway confirmation required.                    |

| Technology appraisal (TA)<br>Titles are hyperlinks to full guidance   | Date of TA Release | Availability of medicine for NHS patients with this medical condition, as indicated by NICE   | Trust Allocation for Action                                      | Trust Action Required before Implementation | Adherence of local formulary to NICE |                              |                                   |                          | Other Information        |               |   |
|---|--------------------|---|--|---|--------------------------------------|------------------------------|-----------------------------------|--------------------------|--------------------------|---------------|---|
|   |                    |   |  |   | Yes (mark 'x' if applicable)         | N/A (mark 'x' if applicable) | Date of local decision (DD/MM/YY) | Time to implement (days) | Responsible Commissioner | Tariff Status | Notes (e.g. rationale, method of making available)  |
| <b>2015-2016</b>  |                    |   |  |   |                                      |                              |                                   |                          |                          |               |   |
| <a href="#">CANGRELO</a> for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy (TA351) | 31/07/2015         | Terminated appraisal - no recommendation  | N/A  | Nil (complete)                              | X                                    |                              | 31/07/2015                        | 0                        | CCG                      | Included      | Terminated appraisal  |
| <a href="#">DEXAMETHASONE INTRAVITREAL IMPLANT</a> for treating diabetic macular oedema (TA349)   | 31/07/2015         | Dexamethasone intravitreal implant - recommended as an option for treating diabetic macular oedema  | Mr Gupta<br>Steve Myers<br>C McFarlane<br>J Esterhuizen          | Nil (complete)                              | X                                    |                              | 29/10/2015                        | 90                       | CCG                      | Excluded      | WSH confirms that this drug will be used in line with NICE guidance. Drug added to formulary. Pathway confirmation required.  |
| <a href="#">EVEROLIMUS</a> for preventing organ rejection in liver transplantation (TA348)  | 31/07/2015         | Everolimus - not recommended for preventing organ rejection in people having a liver transplant.  | N/A  | Nil (complete)                              |                                      | X                            | 31/07/2015                        | 0                        | NHSE                     | Excluded      | This guidance is not relevant to WSH  |
| <a href="#">Naloxegol</a> for treating opioid-induced constipation (TA345)  | 31/07/2015         | Naloxegol - recommended as an option for treating opioid induced constipation in adults whose constipation has not adequately responded to laxatives.   |  | Nil (complete)                              | X                                    |                              | 29/10/2015                        | 90                       | CCG                      | Included      | WSH confirms that this drug will be used in line with NICE guidance. Drug added to formulary. Trust is awaiting confirmation of traffic light status for this drug. |
| <a href="#">Nintedanib</a> for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer (TA347)   | 31/07/2015         | Nintedanib - recommended in combination with docetaxel as an option for treating locally advanced, metastatic or locally recurrent non-small-cell lung cancer of adenocarcinoma histology that has progressed after first-line chemotherapy | Dr Rimmer B<br>van Rooyen P<br>Alderton S<br>Bougatsias          | Nil (complete)                              | X                                    |                              | 29/10/2015                        | 90                       | NHSE                     | Excluded      | WSH confirms that this drug will be used in line with NICE guidance. Drug added to formulary.   |
| <a href="#">Secukinumab</a> for treating moderate to severe plaque psoriasis (TA350)  | 22/07/2015         | Secukinumab - recommended as an option for treating adults with plaque psoriasis  | Dr Fraser-Andrews<br>B van Rooyen P<br>Alderton J<br>Esterhuizen | Nil (complete)                              | X                                    |                              | 20/10/2015                        | 90                       | CCG                      | Excluded      | WSH confirms that this drug will be used in line with NICE guidance. Drug added to formulary. Pathway confirmation required.  |
| <a href="#">Ofatumumab</a> in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (TA344)   | 30/06/2015         | Ofatumumab - recommended in combination with chlorambucil as an option for untreated chronic lymphocytic leukaemia.   | Dr Young-Min B<br>van Rooyen P<br>Alderton S<br>Bougatsias       | Nil (complete)                              | X                                    |                              | 28/09/2015                        | 90                       | NHSE                     | Excluded      | WSH confirms that this drug will be used in line with NICE guidance. Drug added to formulary.   |
| <a href="#">Obinutuzumab</a> in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)   | 30/06/2015         | Obinutuzumab - recommended in combination with chlorambucil, as an option for adults with untreated chronic lymphocytic leukaemia who have comorbidities that make full-dose fludarabine-based therapy unsuitable for them.                 | Dr Young-Min B<br>van Rooyen P<br>Alderton S<br>Bougatsias       | Nil (complete)                              | X                                    |                              | 28/09/2015                        | 90                       | NHSE                     | Excluded      | WSH confirms that this drug will be used in line with NICE guidance. Drug added to formulary.   |
| <a href="#">Vedolizumab</a> for treating moderately to severely active ulcerative colitis (TA342)   | 30/06/2015         | Vedolizumab - recommended as an option for treating moderately to severely active ulcerative colitis (UC) in adults.  | Dr Sharpstone<br>B van Rooyen P<br>Alderton J<br>Esterhuizen     | Nil (complete)                              | X                                    |                              | 28/09/2015                        | 90                       | CCG                      | Excluded      | WSH confirms that this drug will be used in line with NICE guidance. Drug added to formulary. Pathway confirmation required   |
| <a href="#">Apixaban</a> for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)   | 30/06/2015         | Apixaban - recommended as an option for treating and for preventing recurrent deep vein thrombosis and pulmonary embolism in adults.  | Dr Chitnavis B<br>van Rooyen P<br>Alderton J<br>Esterhuizen      | Nil (complete)                              | X                                    |                              | 28/09/2015                        | 90                       | CCG                      | Included      | WSH confirms that this drug will be used in line with NICE guidance. Drug added to formulary.   |
| <a href="#">Ustekinumab</a> for treating active psoriatic arthritis (rapid review of technology appraisal guidance 313) (TA340)   | 30/06/2015         | Ustekinumab - recommended as an option, alone or in combination with methotrexate, for treating active psoriatic arthritis in adults  | Dr O Reilly<br>B van Rooyen P<br>Alderton J<br>Esterhuizen       | Nil (complete)                              | X                                    |                              | 28/09/2015                        | 90                       | CCG                      | Excluded      | WSH confirms that this drug will be used in line with NICE guidance. Drug added to formulary. Pathway confirmation required   |

| Technology appraisal (TA)<br>Titles are hyperlinks to full guidance                     | Date of TA Release | Availability of medicine for NHS patients with this medical condition, as indicated by NICE   | Trust Allocation for Action                                      | Trust Action Required before Implementation | Adherence of local formulary to NICE |                                 |                                      |                                  | Other Information        |               |   |
|---|--------------------|---|--|---|--------------------------------------|---------------------------------|--------------------------------------|----------------------------------|--------------------------|---------------|---|
|   |                    |   |  |   | Yes<br>(mark 'x' if applicable)      | N/A<br>(mark 'x' if applicable) | Date of local decision<br>(DD/MM/YY) | Time to implement<br>(days)      | Responsible Commissioner | Tariff Status | Notes (e.g. rationale, method of making available)  |
| 2015-2016   |                    |   |  |   |                                      |                                 |                                      |                                  |                          |               |   |
| <a href="#">Omalizumab for previously treated chronic spontaneous urticaria (TA339)</a> | 30/06/2015         | <b>Omalizumab</b> - recommended as an option as add-on therapy for treating severe chronic spontaneous urticaria in adults and young people aged 12 years and over. | Dr Fraser-Andrews<br>B van Rooyen<br>P Alderton<br>J Esterhuizen | Nil (complete)                              |                                      | X                               | 28/09/2015                           | 90                               | NHSE                     | Excluded      | NHSE will only commission this treatment from specialist centres. The drug will therefore not be used at WSH. Patients will be referred to a specialist centre. |
|   |                    |   |  |   | 34                                   | 10                              |                                      |                                  |                          |               |   |
|   |                    |   |  |   | % "Yes"                              | % "N/A"                         | –                                    | Average implement time<br>(days) |                          |               |   |
| Adherence statistics for 2015-16  |                    |   |  |   | 77%                                  | 23%                             |                                      | 66                               |                          |               |   |